Monitoring Dual-Cancer Treatment in a Patient With Prostate and Hepatocellular Carcinoma Using Prostate-Specific Membrane Antigen-Directed PET/CT.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
23 Feb 2024
23 Feb 2024
Historique:
medline:
23
2
2024
pubmed:
23
2
2024
entrez:
23
2
2024
Statut:
aheadofprint
Résumé
We report on a 70-year-old man affected with prostate carcinoma (PC) scheduled for prostate-specific membrane antigen (PSMA) PET/CT using 18F-PSMA1007. Because of uptake in the liver and corresponding findings on magnetic resonance, diagnosis of hepatocellular carcinoma (HCC, G1) was established. The patient was then scheduled for antihormonal treatment for PC and locoregional therapy due to HCC. On follow-up PSMA-targeted PET/CT, we observed durable response to PC-associated therapy, whereas hepatic lesions showed progressive disease. As such, we herein report on a dual-cancer targeting molecular imaging strategy to determine disease extent in a patient affected with both PC and HCC, along with potential of monitoring both systemic and locoregional treatment.
Identifiants
pubmed: 38389205
doi: 10.1097/RLU.0000000000005114
pii: 00003072-990000000-00968
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: R.A.W. has received speaker honoraria from Novartis and reports advisory board work for Novartis and Bayer. All other authors declare no conflict of interest.
Références
Thompson SM, Suman G, Torbenson MS, et al. PSMA as a theranostic target in hepatocellular carcinoma: immunohistochemistry and (68) Ga-PSMA-11 PET using cyclotron-produced (68) Ga. Hepatol Commun. 2022;6:1172–1185.
Hirmas N, Leyh C, Sraieb M, et al. (68)Ga-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma. J Nucl Med. 2021;62:1235–1241.
Taneja S, Taneja R, Kashyap V, et al. 68Ga-PSMA uptake in hepatocellular carcinoma. Clin Nucl Med. 2017;42:e69–e70.
Doroudinia A, Chekuri S. 68Ga-PSMA-avid liver metastases from colon cancer, not visualized on FDG PET scan. Clin Nucl Med. 2023;48:e547–e548.
Lawal IO, Pectasides M, Parihar AS, et al. Aberrant vascular anatomy associated with artifactual focal avidity in the liver on PSMA PET. Clin Nucl Med. 2023;48:e455–e457.
Lu Y, Li C. Incidental findings of coexisting metastatic pancreatic cancer in patients with prostate cancer on 18F-prostate-specific membrane antigen PET/CT. Clin Nucl Med. 2022;47:1103–1104.
Jha S, Hemrom A, Shamim SA, et al. 68Ga-PSMA PET/CT detecting metastatic lesion of RCC: missed on 18F-FDG PET/CT. Clin Nucl Med. 2023;48:e294–e296.
Uijen MJM, Derks YHW, Merkx RIJ, et al. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging. 2021;48:4350–4368.